Potential concerns like hair loss with retatrutide and GLP-1 related fatigue have been reported and typically resolve with dose adjustment or stabilization at steady state
Conventional SELEX is experimentally driven and allows for direct, real-world validation of aptamer-target interactions, but it is time-consuming and labor-intensive
This is where GLP-1 medications enter the conversation
In the past 5 years, major therapeutic advances have been made with multiple mechanisms progressing to the clinic and the approval of semaglutide, the first GLP-1RA leading to over 10% weight loss, an amount known to improve many of the complications associated with obesity (7)
First, there must be a clear scientific rationale: why this target, why this compound, and why it could potentially benefit that type of patients
Yes, intranasal doses should be 4060% of equivalent oral doses due to higher bioavailability and direct olfactory-CNS pathways